Algernon Pharmaceuticals Inc (AGNPF)

[shell3]

Need to reread the second paragraph again

The choice of the primary outcome measure will be determined by a pilot study of the first 150 subjects. Subject clinical status (on a 7-point ordinal scale) at day 15 in treatment versus the control group is the default primary endpoint.

The 682 is the Phase 3 part — And I’m no Doctor but I believe that’s what the 682 number has included

JMO

https://clinicaltrials.gov/ct2/show/NCT04382924?term=algernon&draw=1&rank=1